Insmed.
company in Bridgewater, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 42
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Encore supports Insmed's franchise growth.Some support1 report
-
Jim Cramer labeled Insmed as a very speculative investment on July 15, 2025.Some support1 report
-
Insmed established a new R&D hub in Cambridge on July 28, 2025. The company also noted a connection between a key individual and AstraZeneca.Some support1 report
-
Zacks model provides insight into business conditions for Insmed.Some support1 report
-
Insmed reported that revenue from Europe and the rest of the world increased by 48.3% on August 7, 2025.Some support1 report1 development inside
-
Insmed is projected to generate revenue in Europe and Japan.Well supported3 reports
-
Insmed shares added 61.2% on August 7, 2025, significantly outpacing the S&P 500's 7.9% gain.Some support3 reports
-
The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.Well supported4 reports
-
Barchart provided technical buy signals for Insmed on August 19, 2025.Some support1 report
-
FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.Well supported5 reports
No events began in the chosen period. Widen it, or reset.
Around Insmed this week
News at the entities that move Insmed most-
FDA StructuralChris Carr, Georgia Attorney General, seeks stricter state laws following FDA warnings about kratom.Moves Insmed
-
Morgan Stanley Mentioned togetherGEK TERNA is facing issues including fraudulent activities in Greece, leading to banks pre-marketing shares and Santander advising on a capital increase.Moves Insmed
-
Goldman Sachs OperationalGoldman Sachs granted funding to Every Cure, and Asahi Pompey was named head of the Goldman Sachs Foundation.Moves Insmed
-
United Therapeutics OperationalUnited Therapeutics completed facility construction in Minnesota and Texas and submitted an NDA to the FDA.Moves Insmed
-
Leerink partners TransactionalIntuitive Surgical received a Buy rating from Leerink partners, citing increased da Vinci placements and potential benefits from Trump-era tariffs.Moves Insmed
-
Nasdaq StructuralRoyal Bank of Canada lowered its target price for Wingstop, a company traded on Nasdaq.Moves Insmed
Connections
The 9 strongest of 42, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Insmed's ability to market its drugs is structurally dependent on formal regulatory review and approval by the FDA.
-
PPF Operational
Insmed and PPF are engaged in a partnership related to Insmed's planned Phase III clinical studies.
-
United Therapeutics Operational
The companies actively compete in PAH treatments while Insmed supplies a critical prodrug component for United Therapeutics' drug.
-
Goldman Sachs Operational
Goldman Sachs provides financial analysis and coverage for Insmed, which presents to the firm.
-
Nasdaq Structural
Insmed operates as a listed company on the Nasdaq stock exchange.
-
Encore Structural
Encore provides functional support critical to Insmed's continued franchise growth.
-
Morgan Stanley Mentioned together
Morgan Stanley provided investment recommendations and raised price targets for Insmed stock.
-
Leerink partners Transactional
Leerink Partners acted as a joint book-running manager for Insmed during a financial offering.
Show all 9 connections
-
Europe Shared context
Insmed operates and generates revenue within the European market, utilizing offices and research locations across the continent.
History
Events by the month they beganAugust 2026
1 eventJune 2026
10 events- Encore supports Insmed's franchise growth.
- Jim Cramer labeled Insmed as a very speculative investment on July 15, 2025.
- Insmed established a new R&D hub in Cambridge on July 28, 2025. The company also noted a connection between a key individual and AstraZeneca.
- Zacks model provides insight into business conditions for Insmed.
- Insmed reported that revenue from Europe and the rest of the world increased by 48.3% on August 7, 2025.
- Insmed is projected to generate revenue in Europe and Japan.
- Insmed shares added 61.2% on August 7, 2025, significantly outpacing the S&P 500's 7.9% gain.
- The FDA approved Insmed's BRINSUPRI therapy on August 26, 2025, noting market comparisons between the US and EU4 markets.
- Barchart provided technical buy signals for Insmed on August 19, 2025.
- FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.